Follow
James L. Gulley
James L. Gulley
National Cancer Institute
Verified email at mail.nih.gov - Homepage
Title
Cited by
Cited by
Year
Androgen deprivation therapy for prostate cancer
N Sharifi, JL Gulley, WL Dahut
Jama 294 (2), 238-244, 2005
12512005
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer
PW Kantoff, TJ Schuetz, BA Blumenstein, LM Glode, DL Bilhartz, ...
Journal of Clinical Oncology 28 (7), 1099, 2010
11832010
Avelumab, an anti–programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase ib study
AB Apolo, JR Infante, A Balmanoukian, MR Patel, D Wang, K Kelly, ...
Journal of Clinical Oncology 35 (19), 2117, 2017
6262017
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
MR Patel, J Ellerton, JR Infante, M Agrawal, M Gordon, R Aljumaily, ...
The Lancet Oncology 19 (1), 51-64, 2018
5842018
Antibody-dependent cellular cytotoxicity activity of a novel anti–PD-L1 antibody avelumab (MSB0010718C) on human tumor cells
B Boyerinas, C Jochems, M Fantini, CR Heery, JL Gulley, KY Tsang, ...
Cancer immunology research 3 (10), 1148-1157, 2015
572*2015
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer
WL Dahut, JL Gulley, PM Arlen, Y Liu, KM Fedenko, SM Steinberg, ...
Journal of clinical oncology 22 (13), 2532-2539, 2004
4522004
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer
JL Gulley, PM Arlen, A Bastian, S Morin, J Marte, P Beetham, KY Tsang, ...
Clinical Cancer Research 11 (9), 3353-3362, 2005
4242005
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
RA Madan, M Mohebtash, PM Arlen, M Vergati, M Rauckhorst, ...
The lancet oncology 13 (5), 501-508, 2012
3602012
Phase I study of sequential vaccinations with fowlpox-CEA (6D)-TRICOM alone and sequentially with vaccinia-CEA (6D)-TRICOM, with and without granulocyte-macrophage colony …
JL Marshall, JL Gulley, PM Arlen, PK Beetham, KY Tsang, R Slack, ...
Journal of Clinical Oncology 23 (4), 720-731, 2005
3522005
Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial
ML Disis, MH Taylor, K Kelly, JT Beck, M Gordon, KM Moore, MR Patel, ...
JAMA oncology 5 (3), 393-401, 2019
3462019
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
PM Arlen, JL Gulley, C Parker, L Skarupa, M Pazdur, D Panicali, ...
Clinical cancer research: an official journal of the American Association …, 2006
3432006
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
JL Gulley, PM Arlen, RA Madan, KY Tsang, MP Pazdur, L Skarupa, ...
Cancer Immunology, Immunotherapy 59, 663-674, 2010
3402010
Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFβ, in advanced solid tumors
J Strauss, CR Heery, J Schlom, RA Madan, L Cao, Z Kang, E Lamping, ...
Clinical Cancer Research 24 (6), 1287-1295, 2018
3362018
Reviews of evidence regarding interventions to reduce tobacco use and exposure to environmental tobacco smoke
DP Hopkins, PA Briss, CJ Ricard, CG Husten, VG Carande-Kulis, ...
American journal of preventive medicine 20 (2), 16-66, 2001
3342001
Current landscape of immunotherapy in breast cancer: a review
S Adams, ME Gatti-Mays, K Kalinsky, LA Korde, E Sharon, ...
JAMA oncology 5 (8), 1205-1214, 2019
3222019
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label …
JL Gulley, A Rajan, DR Spigel, N Iannotti, J Chandler, DJL Wong, J Leach, ...
The Lancet Oncology 18 (5), 599-610, 2017
3012017
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
CR Heery, G O'Sullivan-Coyne, RA Madan, L Cordes, A Rajan, ...
The Lancet Oncology 18 (5), 587-598, 2017
3002017
Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV‐PSA) in patients with metastatic androgen‐independent prostate cancer
J Gulley, AP Chen, W Dahut, PM Arlen, A Bastian, SM Steinberg, K Tsang, ...
The Prostate 53 (2), 109-117, 2002
2682002
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy
WD Stein, JL Gulley, J Schlom, RA Madan, W Dahut, WD Figg, Y Ning, ...
Clinical Cancer Research 17 (4), 907-917, 2011
2612011
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer
RA Madan, PM Arlen, M Mohebtash, JW Hodge, JL Gulley
Expert opinion on investigational drugs 18 (7), 1001-1011, 2009
2552009
The system can't perform the operation now. Try again later.
Articles 1–20